康方生物维持“买入”评级,目标价115港元

交银国际
Yesterday

一、核心观点与评级维持发布研报称,坚定看好康方生物(87.15,-0.05,-0.06%)(09926),维持“买入”评级及目标价115港元,该行维持依沃西内地及海外销售峰值61亿元人民币的预测。公司宣布依沃西单抗治疗1L PD-L1阳性NSCLC的内地上市申请成功获批,远早于预期。同步公布了III期AK112-303/HARMONi-2研究的第一次OS中期分析结果:HR值0.777,降低死亡风险...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10